BPTH (Bio-Path Holdings) FCF Margin % : 0.00% (As of Dec. 2024)

View and export this data going back to 2008. Start your Free Trial

What is Bio-Path Holdings FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Bio-Path Holdings's Free Cash Flow for the three months ended in Dec. 2024 was $-2.88 Mil. Bio-Path Holdings's Revenue for the three months ended in Dec. 2024 was $0.00 Mil. Therefore, Bio-Path Holdings's FCF Margin % for the quarter that ended in Dec. 2024 was 0.00%.

As of today, Bio-Path Holdings's current FCF Yield % is -810.34%.

The historical rank and industry rank for Bio-Path Holdings's FCF Margin % or its related term are showing as below:

During the past 13 years, the highest FCF Margin % of Bio-Path Holdings was -22959.46%. The lowest was -65276.92%. And the median was -44118.19%.

BPTH's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -127.22
* Ranked among companies with meaningful FCF Margin % only.

Bio-Path Holdings FCF Margin % Historical Data

The historical data trend for Bio-Path Holdings's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Path Holdings FCF Margin % Chart

Bio-Path Holdings Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Get a 7-Day Free Trial

Bio-Path Holdings Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Bio-Path Holdings's FCF Margin %

For the Biotechnology subindustry, Bio-Path Holdings's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bio-Path Holdings's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bio-Path Holdings's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Bio-Path Holdings's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Bio-Path Holdings FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Bio-Path Holdings's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-10.575	/	0
	=	%

Bio-Path Holdings's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-2.881	/	0
	=	%

Bio-Path Holdings FCF Margin % Related Terms

Thank you for viewing the detailed overview of Bio-Path Holdings's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Bio-Path Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bio-Path Holdings Inc (OTCPK:BPTH) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

4710 Bellaire Boulevard, Suite 210, Bellaire, TX, USA, 77401

Website

https://www.biopathholdings.com

Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.

Executives

Aline Sherwood	director	347 BRANDYWINE DRIVE, IRWIN PA 15642
Tamaro Martina Molsbergen	director	1307 SUMMERHILL DRIVE, MALVERN PA 19355
Mark P Colonnese	director	4674 ANDREA POINTE, MARIETTA GA 30062
Peter Henry Nielsen	director, officer: President, CEO & CFO	20651 PRINCE CREEK, KATY TX 77450
Paul Aubert	director	4710 BELLAIRE BOULEVARD, SUITE 210, BELLAIRE TX 77401
Armistice Capital, Llc	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital Master Fund Ltd.	10 percent owner	C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Heath Cleaver	director	4010 BALSAM FIR LN., SPRING TX 77386
Ulrich W. Mueller	officer: COO & Secretary	17841 6TH AVE NW, SHORELINE WA 98177
Amy Sing	director	C/O SAETTLE GENETICS INC, 21823 30TH DRIVE SE, BOTHELL WA 98021
Michael J. Garrison	director	2626 SOUTH LOOP, SUITE 180, HOUSTON TX 77054
Douglas P Morris	director	550 MADISON AVENUE, SUITE 3206, NEW YORK NY 10022
Gillian C Ivers-read	director	C/O PHARMION CORPORATION, 2525 28TH STREET, BOULDER CO 80301
Thomas E Garrison	director	P O BOX 150248, OGDEN UT 84415